fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Fentanyl transdermal system

All products: Limited Use (codes 511)

Sandoz Fentanyl Patch · DIN 02327112 · 12 mcg/hr · Trans Patch

Limited Use, Reason for Use code 511 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 511 required
Write on scriptReason for Use code 511 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 511
Reason for Use code 511 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Sandoz Fentanyl Patch · DIN 02327112 Manufacturer: Sandoz Canada Inc.; listing date 2010-03-02 Health Canada: Marketed since 2010-11-01 · brand SANDOZ FENTANYL PATCH · ATC N02AB03 FENTANYL · form Patch · route Transdermal · ingredients FENTANYL 12 MCG/HOUR · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Fentanyl Patch: Formulary list price $3.32 per unit (the source does not state the unit; exact figure $3.3200). What the ministry pays, not the patient.

Ministry pays: $3.3200 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02327112)

Source record
DIN 02327112: Sandoz Fentanyl Patch Raw flags: sec12=Y, sec3=Y Item: 280808169; group id 402; item number 0961; lccId 00402; manufacturer id SDZ Source form: Trans Patch; strength: 12mcg/hr Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.3200; ministry $3.3200 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02327112 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81243
Interchangeable products
Duragesic 12 · DIN 02280345 · not recorded Teva-Fentanyl · DIN 02311925 · $3.3200
Shortage status: resolved shortage (ended April 14, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02327112
Shortage record checked October 6, 2026

Other products in the same Health Canada class (N02A): coverage varies; not interchangeable

  • Acetaminophen + caffeine + codeine (Teva-Lenoltec No.2): general benefit, not a benefit
  • Acetaminophen + codeine (PMS-Acetaminophen With Codeine): general benefit, not a benefit
  • Hydromorphone (Hydromorph Contin): general benefit, not a benefit
  • Morphine (M-Eslon): general benefit, not a benefit
  • Acetaminophen + oxycodone (Teva-Oxycocet): general benefit, not a benefit
  • Acetylsalicylic acid + oxycodone (Ratio-Oxycodan): general benefit, not a benefit

4 more in the class list below

Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered

Matched class: 28:08:08 Opiate Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE, ACETAMINOPHEN & CODEINE PHOSPHATE, CODEINE PHOSPHATE, HYDROMORPHONE HCL, METHADONE HCL, MORPHINE SULFATE, OXYCODONE HCL & ACETAMINOPHEN, OXYCODONE HCL & ACETYLSALICYLIC ACID 28:08:08 Opiate Agonists

ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 300mg & 15mg & 15mg, 300mg & 15mg & 30mg · Tab

ACETAMINOPHEN & CODEINE PHOSPHATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 160mg & 8mg/5mL, 300mg & 30mg, 300mg & 60mg · O/L, Tab

HYDROMORPHONE HCL

· 28 products · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) · strengths: 4.5mg, 9mg, 3mg, 6mg, 12mg, 18mg, 2mg/mL, 10mg/mL, 1mg/mL, 1mg, 2mg, 4mg, 8mg · CR Cap, Inj Sol-1mL Pk, Oral Sol, Tab

MORPHINE SULFATE

· 35 products · General benefit (31), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 10mg, 15mg, 30mg, 60mg, 100mg, 2mg/mL, 10mg/mL, 15mg/mL, 50mg/mL, 20mg, 50mg, 200mg, 5mg · ER Cap, Inj Sol Amp, Inj Sol-1mL Pk, SR Cap, SR Tab, Tab

OXYCODONE HCL & ACETAMINOPHEN

· 5 products · General benefit (4), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

OXYCODONE HCL & ACETYLSALICYLIC ACID

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE & CODEINE PHOSPHATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg & 15mg, 330mg & 50mg & 40mg & 30mg · Cap

OXYCODONE HCL

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg, 20mg · Tab

TRAMADOL HCL

· 13 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg, 300mg, 50mg · ER Tab, Tab

TRAMADOL HCL & ACETAMINOPHEN

· 12 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 37.5mg & 325mg · Tab

CODEINE PHOSPHATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 15mg, 30mg · Tab

METHADONE HCL

· 16 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg/mL, 1mg, 5mg, 10mg, 25mg · Oral Concentrate, Oral Concentrate (Cherry Flavour), Oral Concentrate (Unflavoured), Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:08:08 and 2 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults: TEVA-FENTANYL (fentanyl transdermal system) is indicated for the management of pain severe enough to require daily, continuous, long-term opioid treatment and:  that is opioid-responsive;  and for which alternative options are inadequate Only for use in patients who are already receiving opioid therapy at a total daily dose of at least 60 mg/day Morphine Equivalents. TEVA-FENTANYL is not indicated as an as-needed (prn) analgesic. The initial dose of TEVA-FENTANYL should be obtained or calculated from the conversion tables (see DOSAGE AND ADMINISTRATION), and must not be higher than that dose which is equivalent to the total dose of opioids the patient is receiving at the time of the switch to the patch. Because serious or life-threatening hypoventilation could occur, TEVA-FENTANYL should not TEVA-FENTANYL (12, 25, 50, 75 and 100 mcg/h) Page 3 of 60 be used in:  non-opioid-tolerant patients  the management of post-operative pain Pediatrics (< 18 years of age): The safety and efficacy of fentanyl transdermal system has not been studied in the pediatric population. Therefore, the… https://pdf.hres.ca/dpd_pm/00066268.PDF PM date: June 10, 2022 Source product: TEVA-FENTANYL; DIN 02282941; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.